Ikerian, RetinAI launch patient management platform
Click Here to Manage Email Alerts
Ikerian AG and its subsidiary RetinAI have launched RetinAI Discovery for Clinics, a software solution designed to improve treatment workflows, referrals and patient management decisions for eye care providers.
“Discovery for Clinics is a powerful tool empowering not only physicians with enhanced AI-powered data insights to optimize outcomes and treatments, but also patients, giving them access to their data,” Carlos Ciller, PhD, CEO and co-founder of Ikerian, said in a company press release.
According to the release, the vendor-neutral platform collects large datasets in a cloud-based repository, where it is then analyzed using the company’s Research Use Only AI algorithms for “accelerated and AI-biomarker based treatment decisions.” The AI models also can be processed using various formats, including DICOM, for OCT and fundus imaging.
In addition, the platform features progression analytics to track trends in patient outcomes and also help patients visualize the progression of their disease. The Discovery Passport feature also allows physicians to share data and questionnaires with patients and supports referral networks and clinical trial participation.
“I have used the RetinAI Discovery platform and find it to be easy to use and provides useful metrics for [age-related macular degeneration], in particular analyzing biomarkers associated with AMD to determine better patient referrals,” Trusit Dave, PhD, BSc, DipTp, MCOptom, FAAO, said in the release.
Read more about
Click Here to Manage Email Alerts